A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma

Haematologica

Volumn 91, Issue 4, 2006, Pages 550-553

  Lefrère, François ^a   Zohar, Sarah ^b   Bresson, Jean Louis ^b   Chevret, Sylvie ^b   Mogenet, Agnès ^b   Audat, Françoise ^b   Durand Zaleski, Isabelle ^b   Ghez, David ^b   Dal Cortivo, Liliane ^b   Piesvaux, Patrick ^b   Cavazzana Calvo, Marina ^b   Varet, Bruno ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

Bayesian; CD34+; Continual reassessment method; Dose finding; G CSF; Leukapheresis; Phase II; Stem cell mobilization

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; AGED; ARTICLE; BAYES THEOREM; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; HUMAN; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; DOUBLE-BLIND METHOD; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKAPHERESIS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 33645958887     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Chao NJ, Schriber JR, Long GD, Negrin RS, Catolico M, Brown BW, et al. Granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993;81:2031-5.
2. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13:2547-55.
3. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002;20:2472-9.
4. Martin-Murea S, Voso MT, Hohaus S, Pforsich M, Fruehauf S, Goldschmidt H, et al. The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haemopoietic progenitor cells during marrow recovery. Br J Haematol 1998;101:582-5.
5. Lefrere F, Delmer A, Levy V, Delarue R, Varet B, Hermine O. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004;89:1275-6.
6. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M, et al. Patients characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83:3787-94.
7. Narabayashi M, Takeyama K, Fukutomi T, Tokuda Y, Tajima T, Okumura A, et al. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group. Jpn J Clin Oncol 1999;29:285-90.
8. Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002;116:468-74.
9. Lefrère F, Belanger C, Audat F, Hermine O, Cavazzana-Calvo M, Amulf B, et al. The dose of G-CSF following chemopriming treatment does not influence stem cell apheresis yield: a retrospective study of 91 cases. Transfusion 1999; 39:1207-11.
10. Smardova L, Engert A, Haverkamp H, Raemakers J, Baars J, Pfistner B, et al. Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cis-platinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma 2005;46:1017-22.
11. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P A, et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002;29:285-90.
12. Endo T, Sato N, Mogi Y, Koizumi K, Nishio M, Fujimoto K, et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:703-7.
13. Zohar S, Chevret S. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design. J Biopharm Stat 2003;13:87-101.
14. Levy V, Zohar S, Porcher R, Chevret S. Alternate designs for conduct and analysis of phase I cancer trials. Blood 2001;98:1275-6.
15. Dreger P, Kloss M, Petersen B, Haferlach T, Loffler H, Loeffler M, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86:3970-8.
16. Kotasek D, Shepherd KM, Sage RE, Dale BM, Norman JE, Charles P, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992;9:11-7.
17. Marit G, Thiessard F, Faberes C, Cony-Makhoul P, Boiron JM, Bernard P, et al. Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study. Leukemia 1998;12:1447-56.
18. Lefrère F, Levy V, Makke J, Audat F, Cavazzana-Calvo M, Miclea JM. Successful peripheral blood stem cell harvesting with granulocyte colony-stimulating factor alone after previous mobilization failure. Haematologica 2004;89:1532-4.
19. Bolwell B, Goormastic M, Dannley R, Andresen S, Overmoyer B, Mendez Z, et al. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10 and 16 μg/kg/d. Bone Marrow Transplant 1997;19:215-9.
20. Toner J, Shapiro J, Laidlaw C, Rischin, Millward M, Wolf M, et al. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: a randomized crossover comparaison. J Clin Oncol 1998;16:3874-9.